Navigation Links
3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
Date:8/24/2010

ney rejection following transplantation. "New Onset Diabetes After Transplant ("NODAT") is common and has become a major concern in transplantation of all organs. In kidney transplantation, it is shown to be associated with inferior long term graft and patient survival while increasing the cost of patient management. Voclosporin has not only demonstrated equal efficacy with improvements in safety, but is easy to use for clinicians which is a major benefit," stated Suphamai (Michael) Bunnapradist, MD, MS, FACP, FASN, Associate Professor of Medicine, UCLA Medical Center. Further details about the phase IIb trial results are available at http://www.newswire.ca/en/releases/archive/April2009/21/c3401.html

"A reduced burden of NODAT in patients on voclosporin at the proposed therapeutic dose was shown in the Phase 2b kidney transplant trial and would represent a significant benefit to patients," added Dr. Foster. "Published literature shows that mean graft survival of 11 years decreases to 8 years with NODAT."

"The worldwide calcineurin inhibitor market in 2009 was at least $3 billion with sales being generated by only two commercially available drugs, cyclosporine and tacrolimus," commented Dr. Foster. "Kidney transplantation represents approximately 60% of all solid organ transplants of which 93% require calcineurin inhibitors as part of their immunosuppressive regimen."

Safe Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. The accuracy of these statements may be impacted by a number of busin
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 3SBio Inc. Announces Results of Annual General Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... The quantum dot market report analyzes the ecosystem of the ... product includes medical devices, display, and others. The others segment ... storage, QD laser, and transistor. The application segment covers the ... The report also provides the geographic view for major regions ... Europe , Asia-Pacific (APAC), and ...
(Date:9/2/2015)... , Sept. 2, 2015 About Duchenne ... X-linked disease, which generally affects the male population. ... weakness. The disease is caused due to mutations ... lack of production of dystrophin (a protein essential ... lack of dystrophin weakens muscle function, causes loss ...
(Date:9/2/2015)... Sept. 2, 2015  Array BioPharma Inc. (Nasdaq: ... Executive Officer, Ron Squarer , will present ... Boston.  The public is welcome to participate in ... BioPharma website.Event: Wells Fargo Securities Healthcare ConferencePresenter: Ron ... 2015Time:  , 10:20 a.m. Eastern Time Webcast: ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3
... May 25, 2011 Each month, millions of women suffer ... of the all-new AZO PMS™ -- the only ... women can now get relief from PMS with a fast ... PMS refers to a wide range of physical ...
... May 25, 2011 Graymark Healthcare, Inc. (NASDAQ: ... services and an innovator in comprehensive care for obstructive sleep ... 1-for-4 reverse stock split, which will be effective after the ... The 1-for-4 reverse stock split will automatically convert all shares ...
Cached Medicine Technology:New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 3Graymark Announces 1-for-4 Reverse Stock Split 2
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located ... geared towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , ... a whole mind-body approach to fitness - we are much more than a gym. ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors ... public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had ... led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... gift from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham ... the gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficacy endpoint data collection, cloud analytics and workflow solutions today announced the ... enables pharmaceutical researchers to participate in interactive programs in which ERT scientists ...
Breaking Medicine News(10 mins):Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
... News) -- New research finds that adults who suffered from ... fever -- are nine times more likely to have allergic ... are based on about 1,400 adults who have been followed ... Study. The study participants were assessed in 1968, when they ...
... TUESDAY, April 19 (HealthDay News) -- About 1 in ... -- meaning the virus becomes resistant to multiple drugs ... European study shows. That drug failure rate is ... maintaining viral load suppression in young patients who begin ...
... Amanda Gardner HealthDay Reporter , TUESDAY, April 19 ... for the diagnosis of Alzheimer,s disease could double the number ... guidelines, issued Tuesday by the Alzheimer,s Association and the U.S. ... the last recommendations, which have been in use since 1984. ...
... TUESDAY, April 19 (HealthDay News) -- People who have ... hospital than they did almost two decades ago, but discharges ... a result, Iowa researchers report. Using Medicare data on ... 2008, the researchers found that hospital stays are now averaging ...
... available in French . , Montreal April ... age, yet the reasons for this increasing forgetfulness have not ... older individuals have reduced learning and memory because their minds ... Published in The Quarterly Journal of Experimental Psychology, ...
... Goodwin HealthDay Reporter , TUESDAY, April 19 (HealthDay ... either had or were going to get all of the ... doctor,s advice on immunizations, two new surveys find. Pediatricians ... years of hype about a supposed autism/MMR (measles, mumps, rubella) ...
Cached Medicine News:Health News:Kids' Eczema, Hay Fever Linked to Allergic Asthma Later 2Health News:Children With HIV at Higher Risk of Drug Resistance 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 2Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 3Health News:Spring-cleaning the mind? 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3
Inquire...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
... the most powerful, productive ... and rich in features, ... a comprehensive authoring environment ... custom interactive multimedia content ...
Medicine Products: